Relapsed or Refractory Multiple Myeloma

Oncology
9
Pipeline Programs
5
Companies
21
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
2
2
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
2100%
+ 7 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
4 programs
2
1
1
QLS32015Phase 31 trial
QLS32015Phase 21 trial
QLS32015Phase 11 trial
QLS4131 InjectionPhase 11 trial
Active Trials
NCT05920876UnknownEst. Aug 2025
NCT06500507Not Yet RecruitingEst. Jan 2027
NCT07018050RecruitingEst. Jul 2028
+1 more trials
Antengene
AntengeneChina - Shanghai
1 program
1
SVdPhase 31 trial
Active Trials
NCT04939142Active Not RecruitingEst. Dec 2025
Novartis
NovartisBASEL, Switzerland
1 program
1
TKI258Phase 25 trials
Active Trials
NCT00243763Terminated64
NCT01421004Completed166Est. Jul 2014
NCT02720926Terminated3Est. Jan 2012
+2 more trials
Moderna
ModernaCAMBRIDGE, MA
2 programs
1
1
mRNA-2808Phase 1/2RNA Therapeutic1 trial
mRNA-2736Phase 1RNA Therapeutic1 trial
Active Trials
NCT05918250Withdrawn0Est. May 2026
NCT07116616Recruiting166Est. Jun 2032
LaNova Medicines
LaNova MedicinesChina - Shanghai
1 program
1
LM-305Phase 1/21 trial
Active Trials
NCT05647512WithdrawnEst. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Qilu PharmaceuticalQLS32015
AntengeneSVd
Qilu PharmaceuticalQLS32015
NovartisTKI258
NovartisTKI258
NovartisTKI258
NovartisTKI258
ModernamRNA-2808
LaNova MedicinesLM-305
NovartisTKI258
Qilu PharmaceuticalQLS4131 Injection
ModernamRNA-2736
Qilu PharmaceuticalQLS32015
NovartisTKI258
NovartisTKI258

Showing 15 of 20 trials with date data

Clinical Trials (21)

Total enrollment: 798 patients across 21 trials

NCT07138209Qilu PharmaceuticalQLS32015

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Start: Nov 2025Est. completion: Dec 2029
Phase 3Recruiting
NCT04939142AntengeneSVd

A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Start: Jul 2021Est. completion: Dec 2025
Phase 3Active Not Recruiting
NCT07018050Qilu PharmaceuticalQLS32015

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Start: Sep 2025Est. completion: Jul 2028
Phase 2Recruiting
NCT01058434NovartisTKI258

Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

Start: May 2010Est. completion: Feb 201343 patients
Phase 2Completed
NCT00831792NovartisTKI258

TKI258 in Castrate Resistant Prostate Cancer

Start: Apr 2010Est. completion: Jun 201746 patients
Phase 2Completed
NCT00790426NovartisTKI258

Phase II Study of TKI258 in Advanced Urothelial Carcinoma

Start: Mar 2010Est. completion: Apr 201244 patients
Phase 2Completed
NCT00958971NovartisTKI258

Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer

Start: Jul 2009Est. completion: Mar 201143 patients
Phase 2Completed
NCT07116616ModernamRNA-2808

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Start: Sep 2025Est. completion: Jun 2032166 patients
Phase 1/2Recruiting
NCT05647512LaNova MedicinesLM-305

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Start: Jan 2023Est. completion: Dec 2025
Phase 1/2Withdrawn
NCT00303251NovartisTKI258

Safety of TKI258 in Advanced/Metastatic Melanoma Subjects

Start: Apr 200647 patients
Phase 1/2Completed
NCT00243763NovartisTKI258

TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma

64 patients
Phase 1Terminated
NCT06500507Qilu PharmaceuticalQLS4131 Injection

A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma

Start: Aug 2024Est. completion: Jan 2027
Phase 1Not Yet Recruiting
NCT05918250ModernamRNA-2736

mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Start: Aug 2023Est. completion: May 20260
Phase 1Withdrawn
NCT05920876Qilu PharmaceuticalQLS32015

A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma

Start: Jun 2023Est. completion: Aug 2025
Phase 1Unknown
NCT01421004NovartisTKI258

Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors

Start: Dec 2011Est. completion: Jul 2014166 patients
Phase 1Completed
NCT02720926NovartisTKI258

Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer

Start: Sep 2011Est. completion: Jan 20123 patients
Phase 1Terminated
NCT01155713NovartisTKI258

Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors

Start: Jul 2010Est. completion: Nov 201363 patients
Phase 1Completed
NCT01471548NovartisTKI258

Phase I Dose Escalating Study of TKI258

Start: Sep 2008Est. completion: May 201231 patients
Phase 1Completed
NCT00669097NovartisTKI258

Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies

Start: Apr 200813 patients
Phase 1Completed
NCT00279773NovartisTKI258

Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia

Start: Sep 200434 patients
Phase 1Terminated
NCT01270906NovartisTKI258

Safety of CHIR-258 (TKI258) in Advanced Solid Tumors

Start: Dec 200335 patients
Phase 1Terminated

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 798 patients
5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)